Applied BioCode Gross Profit
The Gross Profit of Applied BioCode (6598.TW) as of Aug 2, 2026 is 260.89 M TWD. In the previous year, Gross Profit was 204.00 M TWD — a change of 27.89% (higher).
Get this data via API
Financial Data API
Gross Profit
260.89 MTWD
YoY
27.89%
Last updated:
Gross Profit of Applied BioCode is 2026 260.89 M TWD. Gross Profit of Applied BioCode was 2025 204.00 M TWD. It decreases by 27.89% higher compared to the previous year.
The Applied BioCode Gross Profit history
3 Years
10 Years
25 Years
Max
GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2019
50.59 base
Jan 1, 2020
64.72 base
Jan 1, 2021
59.18 base
Jan 1, 2022
60.00 base
Jan 1, 2023
68.01 base
Jan 1, 2024
59.46 base
Jan 1, 2025
54.90 base
Jan 1, 2026 (e)
0.00 base
| YEAR | GROSS MARGIN (%) |
|---|---|
| 2026 est | - |
| 2025 | 54.90 |
| 2024 | 59.46 |
| 2023 | 68.01 |
| 2022 | 60.00 |
| 2021 | 59.18 |
| 2020 | 64.72 |
| 2019 | 50.59 |
| 2018 | 45.05 |
| 2017 | 33.32 |
| 2016 | 41.62 |
| 2015 | 26.84 |
| 2014 | 17.95 |
| 2013 | 7.58 |
Access this data via the Eulerpool API
Applied BioCode Revenue
Applied BioCode Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
104.69 M TWD
-273.46 M TWD
-280.07 M TWD
Jan 1, 2020
299.02 M TWD
-99.16 M TWD
-103.50 M TWD
Jan 1, 2021
319.96 M TWD
-162.31 M TWD
-165.20 M TWD
Jan 1, 2022
390.30 M TWD
-181.93 M TWD
-184.73 M TWD
Jan 1, 2023
395.17 M TWD
-186.70 M TWD
-164.20 M TWD
Jan 1, 2024
343.07 M TWD
-277.67 M TWD
-260.81 M TWD
Jan 1, 2025
475.20 M TWD
-223.33 M TWD
-201.20 M TWD
Jan 1, 2026 (e)
0.00 TWD
0.00 TWD
0.00 TWD
Applied BioCode Margins
Applied BioCode stock margins
The Applied BioCode margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Applied BioCode. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Applied BioCode.
3 Years
5 Years
10 Years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
50.59 %
-261.20 %
-267.52 %
Jan 1, 2020
64.72 %
-33.16 %
-34.61 %
Jan 1, 2021
59.18 %
-50.73 %
-51.63 %
Jan 1, 2022
60.00 %
-46.61 %
-47.33 %
Jan 1, 2023
68.01 %
-47.25 %
-41.55 %
Jan 1, 2024
59.46 %
-80.94 %
-76.02 %
Jan 1, 2025
54.90 %
-47.00 %
-42.34 %
Jan 1, 2026 (e)
54.90 %
0.00 %
0.00 %
Applied BioCode Stock analysis
What does Applied BioCode do? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases.
The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics.
One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples.
Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment.
Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment.
Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases.
Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways.
In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Applied BioCode stock
Gross Profit of Applied BioCode is 260.89 M TWD in 2026.
Access this data via the Eulerpool API
Income Statement — Applied BioCode
All Key Metrics — Applied BioCode
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth